← Back to Home

Kelun’s TROP2 ADC Makes Another Push Into First-Line Lung Cancer, With a Chemotherapy-Sparing Signal Emerging in PD-L1-Negative Patients

In PD-L1-negative nonsquamous lung cancer, where responses to immunotherapy are less favorable, sac-TMT plus Keytruda delayed disease worsening in a Phase 3 trial, moving the competition around ADC plus immunotherapy from concept into a narrower, harder-to-treat clinical setting.

By SURL BioNews

For advanced non-small cell lung cancer, every advance in first-line treatment is not simply the addition of another drug combination. The real question is whether, in patients whose benefit from immune checkpoint inhibitors is more limited and who lack clear driver gene mutations, a more precise and more manageable path than conventional platinum-containing chemotherapy can be found. Kelun-Biotech’s TROP2 antibody-drug conjugate sacituzumab tirumotecan is now delivering a new Phase 3 signal in this gap.

Kelun-Biotech announced that the Phase 3 OptiTROP-Lung06 clinical trial met its primary endpoint at a prespecified interim analysis. The randomized, open-label, multicenter study evaluated sac-TMT plus pembrolizumab as first-line treatment in patients with PD-L1 TPS of less than 1%, no driver gene mutations, and locally advanced or metastatic nonsquamous non-small cell lung cancer. The control arm was pembrolizumab plus pemetrexed and platinum-based chemotherapy.

According to the company announcement and China securities disclosures, the independent data monitoring committee confirmed that the trial met its endpoint at the interim analysis. Progression-free survival, assessed by blinded independent central review, showed a statistically significant and clinically meaningful improvement. Overall survival is currently described as showing a positive trend, but full data, hazard ratios, or medians have not yet been released. The weight of this result therefore still requires more precise interpretation once subsequent medical conference or journal data become available.

On safety, the disclosed information said no new safety signals were observed. This is especially important for an ADC entering first-line treatment, because the treatment population is no longer limited to patients with few later-line options, but includes people who may receive combination therapy for a long period from the start of treatment. To truly rewrite the standard of care, improved efficacy must be evaluated together with toxicity management, discontinuation rates, quality of life, and sequencing with subsequent treatments.

sac-TMT is an antibody-drug conjugate targeting TROP2. CancerNetwork reported that its design includes a bifunctional linker and carries a belotecan-derived topoisomerase I inhibitor payload, with a drug-to-antibody ratio of approximately 7.4. TROP2 is expressed at elevated levels in multiple epithelial tumors and has become an important target in the lung cancer ADC race in recent years. But the same target does not automatically guarantee clinical success; linker stability, payload release, bystander effect, and therapeutic window are where different ADCs truly begin to diverge.

Background Context

What makes this result distinctive is that it fills in one piece of the puzzle for the PD-L1-negative population. sac-TMT plus pembrolizumab had previously been reported to meet its endpoint in a first-line non-small cell lung cancer trial in PD-L1-positive patients. Now, with a positive PFS signal in PD-L1-negative, nonsquamous patients without driver gene mutations, ADC plus immunotherapy is no longer merely a strategy for patients with more favorable immune responses, but is beginning to challenge a treatment area more dependent on chemotherapy.

Kelun-Biotech said it will communicate with the Center for Drug Evaluation of China’s National Medical Products Administration regarding the study results. Regulatory review will next face several key questions: whether the PFS improvement can translate into a more mature overall survival benefit, whether the toxicity profile is sufficient to support long-term first-line use, and whether undisclosed subgroup data show consistent benefit. For patients, this is not a conclusion that chemotherapy can be replaced immediately; for lung cancer drug development, however, it is another clear signal that TROP2 ADCs are moving toward the central battlefield of first-line treatment.

References

  1. Kelun-Biotech via PR Newswire
  2. Shanghai Securities News / cnstock.com
  3. CancerNetwork